With the recent approval of Jardiance in the US, Eli Lilly and partner Boehringer Ingelheim (BI) “have taken another step towards owning the most comprehensive diabetes portfolio in the industry”, according to research and consulting firm GlobalData.
With the recent approval of Jardiance in the US, Eli Lilly and partner Boehringer Ingelheim (BI) “have taken another step towards owning the most comprehensive diabetes portfolio in the industry”, according to research and consulting firm GlobalData.
Jardiance is expected to be competitive in a market set to more than double in value over the next 10 years, driven primarily by the dramatic increase in disease prevalence. Although the type 2 diabetes market is crowded with ‘me-too’ drugs, GlobalData’s Valentina Gburcik comments that “Eli Lilly and BI have already proved themselves experts at successfully marketing such treatments. This has been demonstrated by Tradjenta… Despite its third-to-market status, Tradjenta is still stealing patient share from Merck’s Januvia.”
While one of Lilly’s main insulin products, Humalog, lost patent protection in 2013 and is about to face stiff competition from biosimilars and ultra-fast formulations of the same drug, the Lilly and BI partnership is strategically placed to be a future diabetes leader, says Gburcik,
“The companies will soon market drugs from every anti-diabetes class, which will strengthen their relationship with buyers,” she adds.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.